NASDAQ:HTBX - Heat Biologics Stock Price, Forecast & News

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

Heat Biologics shares reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

Heat Biologics Inc (NASDAQ:HTBX) posted its quarterly earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.05. The biopharmaceutical company earned $1.84 million during the quarter, compared to the consensus estimate of $1.50 million. Heat Biologics had a negative net margin of 695.62% and a negative return on equity of 88.07%. View Heat Biologics' Earnings History.

Heat Biologics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Heat Biologics.

3 brokers have issued 1 year price objectives for Heat Biologics' stock. Their forecasts range from $6.00 to $8.00. On average, they anticipate Heat Biologics' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 2,700.0% from the stock's current price. View Analyst Price Targets for Heat Biologics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heat Biologics.

Media coverage about HTBX stock has trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Heat Biologics earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Heat Biologics.

Heat Biologics saw a decrease in short interest in January. As of January 15th, there was short interest totalling 469,500 shares, a decrease of 17.8% from the December 31st total of 571,400 shares. Based on an average trading volume of 384,800 shares, the short-interest ratio is presently 1.2 days. Approximately 1.5% of the shares of the stock are short sold. View Heat Biologics' Current Options Chain.

Some companies that are related to Heat Biologics include SCYNEXIS (SCYX), Aclaris Therapeutics (ACRS), Alpine Immune Sciences (ALPN), DiaMedica Therapeutics (DMAC), American Brivision (Holding) (ABVC), Processa Pharmaceuticals (PCSA), Bellicum Pharmaceuticals (BLCM), Leap Therapeutics (LPTX), Aridis Pharmaceuticals (ARDS), Q BioMed (QBIO), Acasti Pharma (ACST), IntelGenx Technologies (IGXT), resTORbio (TORC), Vascular Biogenics (VBLT) and Zafgen (ZFGN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Frontier Communications (FTR), Palatin Technologies (PTN), Alibaba Group (BABA), Opko Health (OPK), Juno Therapeutics (JUNO), TherapeuticsMD (TXMD), Synergy Pharmaceuticals (SGYP), Gevo (GEVO), Sophiris Bio (SPHS) and TrovaGene (TROV).

Heat Biologics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.82%) and Virtu Financial LLC (0.10%). View Institutional Ownership Trends for Heat Biologics.

HTBX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Virtu Financial LLC. View Insider Buying and Selling for Heat Biologics.

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HTBX stock can currently be purchased for approximately $0.25.

Heat Biologics has a market capitalization of $14.36 million and generates $5.79 million in revenue each year. The biopharmaceutical company earns $-15,730,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Heat Biologics employs 30 workers across the globe.View Additional Information About Heat Biologics.

The official website for Heat Biologics is http://www.heatbio.com/.

Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27560. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]